Plasma Derived Therapy Market Players:
- CSL Behring
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- ADMA Biologics, Inc.
- Bio Products Laboratory Ltd.
- Biotest AG
- Grifols, SA
- Kedrion S.p.A
- Octapharma AG
- Pfizer Inc.
- SK Plasma
- Kamada Pharmaceuticals
The major players in the plasma derived therapy market are offering a detailed portfolio of demand for plasma-derived products. These companies are developing and delivering high-quality medicines and therapies using plasma that treat people with rare and serious diseases.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of plasma derived therapy is assessed at USD 25.86 billion.
The global plasma derived therapy market size was valued at over USD 24.31 billion in 2025 and is expected to expand at a CAGR of around 7.1%, surpassing USD 48.27 billion revenue by 2035.
North America plasma derived therapy market will hold more than 44% share by 2035, fueled by government and private initiatives encouraging therapeutic systems.
Key players in the market include CSL Behring, ADMA Biologics, Inc., Bio Products Laboratory Ltd., Biotest AG, Grifols, SA, Kedrion S.p.A, Octapharma AG, Pfizer Inc., SK Plasma, Kamada Pharmaceuticals.
